Piper Sandler Forecasts Strong Price Appreciation for Allogene Therapeutics (NASDAQ:ALLO) Stock

Allogene Therapeutics (NASDAQ:ALLO) had its price objective raised by equities researchers at Piper Sandler from $7.00 to $8.00 in a research note issued on Friday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Piper Sandler’s target price indicates a potential upside of 233.33% from the company’s previous close.

Several other equities analysts have also recently weighed in on ALLO. Citizens Jmp upgraded shares of Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 price objective on the stock in a research note on Friday, January 9th. Citigroup upgraded shares of Allogene Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Friday, January 9th. UBS Group initiated coverage on shares of Allogene Therapeutics in a report on Wednesday, January 7th. They set a “buy” rating and a $8.00 target price for the company. Finally, Wall Street Zen upgraded shares of Allogene Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, February 22nd. Ten equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $8.50.

Allogene Therapeutics Stock Performance

Allogene Therapeutics stock opened at $2.40 on Friday. Allogene Therapeutics has a one year low of $0.86 and a one year high of $2.80. The stock has a fifty day moving average of $1.94 and a 200 day moving average of $1.51. The stock has a market cap of $539.35 million, a PE ratio of -2.76 and a beta of 0.50.

Allogene Therapeutics (NASDAQ:ALLO) last announced its earnings results on Thursday, March 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.08. As a group, sell-side analysts predict that Allogene Therapeutics will post -1.28 EPS for the current fiscal year.

Insider Activity

In other Allogene Therapeutics news, EVP Zachary Roberts sold 35,700 shares of Allogene Therapeutics stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $1.77, for a total transaction of $63,189.00. Following the transaction, the executive vice president owned 581,166 shares of the company’s stock, valued at $1,028,663.82. The trade was a 5.79% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO David D. Chang sold 95,269 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $1.80, for a total transaction of $171,484.20. Following the completion of the transaction, the chief executive officer owned 5,185,862 shares of the company’s stock, valued at approximately $9,334,551.60. The trade was a 1.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 222,987 shares of company stock worth $396,969 in the last quarter. 13.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of ALLO. Savant Capital LLC bought a new position in Allogene Therapeutics in the 3rd quarter worth $27,000. Russell Investments Group Ltd. raised its holdings in Allogene Therapeutics by 11,159.8% during the third quarter. Russell Investments Group Ltd. now owns 21,844 shares of the company’s stock valued at $27,000 after acquiring an additional 21,650 shares during the period. Caitong International Asset Management Co. Ltd raised its holdings in Allogene Therapeutics by 5,267.6% during the third quarter. Caitong International Asset Management Co. Ltd now owns 24,047 shares of the company’s stock valued at $30,000 after acquiring an additional 23,599 shares during the period. Mercer Global Advisors Inc. ADV purchased a new position in shares of Allogene Therapeutics in the third quarter valued at about $30,000. Finally, Brighton Jones LLC boosted its stake in shares of Allogene Therapeutics by 81.6% in the third quarter. Brighton Jones LLC now owns 25,168 shares of the company’s stock worth $31,000 after acquiring an additional 11,311 shares during the period. Hedge funds and other institutional investors own 83.63% of the company’s stock.

Allogene Therapeutics News Summary

Here are the key news stories impacting Allogene Therapeutics this week:

• Positive Sentiment: Canaccord Genuity reaffirmed a “buy” rating and set a $14.00 price target (huge upside vs. current levels), which could attract bargain-hunting and institutional interest. Benzinga
• Positive Sentiment: Piper Sandler raised its price target from $7.00 to $8.00 and maintained an “overweight” rating, signaling improved sell-side confidence in ALLO’s commercial/clinical outlook. Benzinga TickerReport
• Positive Sentiment: Q4 results: ALLO reported a narrower-than-expected loss (EPS -$0.17 vs. consensus -$0.25), highlighted expense reductions, and said cash should fund operations into 2028 — all supportive of near-term financial stability and de-risking. Zacks
• Neutral Sentiment: The company filed its full Q4/FY2025 press release and provided a business update detailing pipeline progress and finances; investors can review details for clinical timelines and cash burn assumptions. GlobeNewswire
• Neutral Sentiment: Earnings call transcript published — useful for details on trial milestones, timelines, and management commentary but not new headline news by itself. Seeking Alpha
• Neutral Sentiment: Short-interest notices in the feed report a “significant increase” but show inconsistent/zero values (likely data/reporting noise); monitor filings for any confirmed rise in short interest. (No reliable link available in the report.)

Allogene Therapeutics Company Profile

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.

The company’s pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.